Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis
Alice T. Shaw(Dana-Farber Cancer Institute), D. Ross Camidge(University of Colorado Denver), Marileila Varella‐Garcia(University of Colorado Anschutz Medical Campus), Mohit Butaney(Brigham and Women's Hospital), Robert C. Doebele(Aurora University), Yiyun Tang(Southwest University), Jeffrey A. Engelman(Cancer Research Center), Daniel B. Costa(Beth Israel Deaconess Medical Center), Geoffrey I. Shapiro(Brigham and Women's Hospital), Benjamin Solomon(Peter MacCallum Cancer Centre), Yung‐Jue Bang(Seoul National University), A. John Iafrate(Massachusetts General Hospital), Gregory J. Riely(Memorial Sloan Kettering Cancer Center), Keith D. Wilner(Pfizer (United States)), Robert G. Maki(Memorial Sloan Kettering Cancer Center), Justin F. Gainor(Harvard University), Sai‐Hong Ignatius Ou(University of California, Irvine Medical Center), Jeffrey W. Clark(Massachusetts General Hospital), Kimary Kulig(Pfizer (United States)), Eunice L. Kwak(Harvard University), Ravi Salgia(City Of Hope National Medical Center), Beow Y. Yeap(Harvard University), Paulina Selaru(Pfizer (United States))
Cited by 903
Related Papers
International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma
|Journal of Thoracic Oncology|2011|4.8k
Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2010|4.5k
<i>MET</i> Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
|Science|2007|4.5k
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
|Nature Genetics|2019|4.4k